Hosted on MSN3mon
Cardiff Oncology announces positive colorectal data and $40m stock oversubscription
US-based clinical-stage biotechnology company Cardiff Oncology has announced positive initial data from its randomised Phase II clinical trial evaluating onvansertib in combination with standard ...
Nasdaq1mon
Cardiff Oncology Reports Positive Initial Efficacy Data for Onvansertib in Metastatic Colorectal Cancer and Secures $40 Million Financing
Cardiff Oncology, Inc. announced positive results from its ongoing first-line clinical trial of onvansertib in RAS-mutated metastatic colorectal cancer (mCRC), showcasing a 64% response rate in ...